{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=16",
    "query": {
      "condition": "Melanoma, Skin",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 2054,
    "total_pages": 206,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma%2C+Skin&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T05:52:07.278Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02680184",
      "title": "Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "CMP-001",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 199,
      "start_date": "2016-04-12",
      "completion_date": "2022-12-06",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02680184"
    },
    {
      "nct_id": "NCT06216938",
      "title": "RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Vusolimogene oderparepvec (RP1)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Yana Najjar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-03-07",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06216938"
    },
    {
      "nct_id": "NCT02223052",
      "title": "Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematological Neoplasms",
        "Non-Hodgkin's Lymphoma",
        "Hodgkin's Lymphoma",
        "Lymphoma",
        "Multiple Myeloma",
        "Acute Myeloid Leukemia",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Neoplasms",
        "Melanoma",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Glioblastoma Multiforme",
        "Osteosarcoma",
        "Sarcoma",
        "Thyroid Cancer",
        "Genitourinary"
      ],
      "interventions": [
        {
          "name": "CC-486",
          "type": "DRUG"
        },
        {
          "name": "Vidaza",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2014-10-27",
      "completion_date": "2018-12-18",
      "has_results": false,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02223052"
    },
    {
      "nct_id": "NCT02012231",
      "title": "Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Thyroid Cancer",
        "Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Cholangiocarcinoma",
        "Histiocytosis",
        "Hairy Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "PLX8394",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fore Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2014-02",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Salt Lake City, Utah • Spokane, Washington",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02012231"
    },
    {
      "nct_id": "NCT01621295",
      "title": "Assessing the Patient Experience in Cancer Care",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Brain Neoplasm",
        "Breast Neoplasm",
        "Endocrine Gland Neoplasm",
        "Gastrointestinal Neoplasm",
        "Genitourinary Neoplasm",
        "Gynecological Neoplasm",
        "Head and Neck Neoplasm",
        "Lung Neoplasm",
        "Melanoma",
        "Sarcoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 408,
      "start_date": "2012-05",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Rochester, Minnesota",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01621295"
    },
    {
      "nct_id": "NCT02082665",
      "title": "Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Rosuvastatin10 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 3 mg syrup",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib 75 mg capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-02-19",
      "completion_date": "2016-08-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-24",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02082665"
    },
    {
      "nct_id": "NCT02339571",
      "title": "A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Elastography",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2015-11-23",
      "completion_date": "2033-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 763,
      "location_summary": "Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 494 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02339571"
    },
    {
      "nct_id": "NCT00071981",
      "title": "Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "melanoma helper peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "multi-epitope melanoma peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tetanus peptide melanoma vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2005-05-09",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 65,
      "location_summary": "Palo Alto, California • Stanford, California • Lewes, Delaware + 50 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071981"
    },
    {
      "nct_id": "NCT01931644",
      "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "All Diagnosed Health Conditions",
        "ADD/ADHD",
        "Alopecia Areata",
        "Ankylosing Spondylitis",
        "Asthma",
        "Atopic Dermatitis Eczema",
        "Beta Thalassemia",
        "Bipolar Disorder",
        "Breast Cancer",
        "Celiac Disease",
        "Cervical Cancer",
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Chronic Kidney Diseases",
        "Chronic Obstructive Pulmonary Disease",
        "Colon Cancer",
        "Colorectal Cancer",
        "Crohn's Disease",
        "Cystic Fibrosis",
        "Depression",
        "Diabetes Mellitus",
        "Duchenne Muscular Dystrophy",
        "Endometriosis",
        "Epilepsy",
        "Facioscapulohumeral Muscular Dystrophy",
        "G6PD Deficiency",
        "General Anxiety Disorder",
        "Hepatitis B",
        "Hereditary Hemorrhagic Telangiectasia",
        "HIV/AIDS",
        "Human Papilloma Virus",
        "Huntington's Disease",
        "Idiopathic Thrombocytopenic Purpura",
        "Insomnia",
        "Kidney Cancer",
        "Leukemia",
        "Lung Cancer",
        "Lupus Nephritis",
        "Lymphoma",
        "Melanoma",
        "Multiple Myeloma",
        "Multiple Sclerosis",
        "Myositis",
        "Myotonic Dystrophy",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Parkinson's Disease",
        "Polycystic Kidney Diseases",
        "Prostate Cancer",
        "Psoriasis",
        "Psoriatic Arthritis",
        "Rosacea",
        "Scleroderma",
        "Sickle Cell Anemia",
        "Sickle Cell Trait",
        "Sjogren's Syndrome",
        "Skin Cancer",
        "Spinal Muscular Atrophy",
        "Systemic Lupus Erythematosus",
        "Thrombotic Thrombocytopenic Purpura",
        "Trisomy 21",
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sanguine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 17667,
      "start_date": "2013-07",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01931644"
    },
    {
      "nct_id": "NCT05086692",
      "title": "A Beta-only IL-2 ImmunoTherapY Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Unresectable Solid Tumor",
        "Clear Cell Renal Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Non-Small Cell Lung Cancer Squamous",
        "Non-Small Cell Lung Cancer Non-squamous",
        "Colorectal Cancer (MSI-H)",
        "Gastric Cancer",
        "Cervical Cancer",
        "Basal Cell Carcinoma",
        "Bladder Cancer",
        "Merkel Cell Carcinoma",
        "Squamous Cell Carcinoma of Head and Neck",
        "Cutaneous Squamous Cell Carcinoma",
        "Pleural Mesothelioma",
        "Esophageal Cancer",
        "Endometrial Carcinoma",
        "Solid Tumor",
        "Solid Tumor, Adult",
        "MSI-H Solid Malignant Tumor",
        "Cancer With A High Tumor Mutational Burden",
        "Epithelial Ovarian Carcinoma",
        "Primary Peritoneal Cancer",
        "Gastroesophageal Junction (GEJ) Cancer",
        "Acral Melanoma",
        "Mucosal Melanoma",
        "Cutaneous Melanoma",
        "DMMR Solid Malignant Tumor",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "MSI-H Cancer",
        "DMMR Cancer",
        "Pancreas Adenocarcinoma (MSI-H)",
        "Skin Cancer",
        "Viral Cancer",
        "Cervical Cancers",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "MDNA11",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medicenna Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2021-08-27",
      "completion_date": "2028-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-19T05:52:07.278Z",
      "location_count": 7,
      "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05086692"
    }
  ]
}